<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30289">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02150317</url>
  </required_header>
  <id_info>
    <org_study_id>EHBHKY2013-001-08</org_study_id>
    <nct_id>NCT02150317</nct_id>
  </id_info>
  <brief_title>Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma</brief_title>
  <acronym>TACE</acronym>
  <official_title>A Prospective Randomized Trial Comparing Transcatheter Arterial Chemoembolization (TACE) Followed by Sorafenib Versus TACE Alone for Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Hepatobiliary Surgery Hospital</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE)
      followed by Sorafenib with TACE alone in patients with advanced hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>the overall survival rate of each group</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>TACE+Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TACE followed by Sorafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TACE alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE+Sorafenib</intervention_name>
    <description>TACE followed by Sorafenib</description>
    <arm_group_label>TACE+Sorafenib</arm_group_label>
    <other_name>TACE followed by Sorafenib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>TACE alone</description>
    <arm_group_label>TACE</arm_group_label>
    <other_name>TACE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients &gt; 18 years and &lt;=70 years of age.

          -  at least 2 radiologic imaging showing characteristic features of hepatocellular
             carcinoma  or cytologic/histologic evidence.

          -  tumor in liver and radiologically definable vascular invasion or extrahepatic
             metastasis.

          -  Criteria of liver function: Child A-B level, serum bilirubin ≤ 1.5 times the upper
             limit of normal value,alanine aminotransferase and aspartate aminotransferase ≤ 2
             times the upper limit of normal value.

          -  No dysfunction in major organs; Blood routine, kidney function, cardiac function and
             lung function are basically normal.

          -  Hb ≥90g/L,white blood cell count ≥3.000 cells/mm³,platelets ≥80.000 cells/mm³

          -  Patients who can understand this trial and have signed information consent

        Exclusion Criteria:

          -  Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction,which may
             affect the treatment of liver cancer.

          -  Patients with other diseases which may affect the treatment mentioned.

          -  Patients with a medical history of other malignant tumors.

          -  Subjects participating in other clinical trials.

          -  liver function:Child C.

          -  no pathological evidence of hepatocellular carcinoma.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ai-jun Li, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ai-jun Li, M.D.</last_name>
    <phone>0086-21-81875531</phone>
    <email>yinlei409@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lei Yin, M.D.</last_name>
    <phone>0086-21-81875532</phone>
    <email>dermatology2008@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Surgery Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ai-jun Li, M.D.</last_name>
      <phone>0086-021-81875531</phone>
      <email>yinlei409@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Lei Yin, M.D.</last_name>
      <phone>0086-021-81875532</phone>
      <email>dermatology2008@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>May 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Hepatobiliary Surgery Hospital</investigator_affiliation>
    <investigator_full_name>ShenFeng</investigator_full_name>
    <investigator_title>vice president of the Eastern Hepatobiliary Surgery Hospital</investigator_title>
  </responsible_party>
  <keyword>Carcinoma, Hepatocellular</keyword>
  <keyword>Chemoembolization, Therapeutic</keyword>
  <keyword>Sorafenib</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
